Bill Haney, Skyhawk co-founder and CEO (Dave Pedley/Getty Images for SXSW)

A busy, buzzy Ver­tex finds a high-pro­file part­ner in the RNA-drug­ging world to launch a fresh dis­cov­ery ef­fort

As Ver­tex be­gan ze­ro­ing in on launch­ing its big com­bo for cys­tic fi­bro­sis, the oft-laud­ed biotech start­ed to se­lec­tive­ly snap up new tech­nolo­gies that promised to break the ther­a­peu­tic mold on the way some dis­eases are treat­ed.

There was the Sem­ma buy­out, look­ing for a cure for di­a­betes. There was a deal with CRISPR Ther­a­peu­tics that just pro­duced some land­mark da­ta on cur­ing sick­le cell dis­ease. They bought Ex­on­ics, with a gene edit­ing ap­proach to cur­ing Duchenne mus­cu­lar dy­s­tro­phy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.